Your browser is no longer supported. Please, upgrade your browser.
LGND [NASD]
Ligand Pharmaceuticals Incorporated
Index- P/E29.44 EPS (ttm)4.00 Insider Own3.20% Shs Outstand16.69M Perf Week-5.78%
Market Cap1.96B Forward P/E28.43 EPS next Y4.14 Insider Trans-4.97% Shs Float15.90M Perf Month-24.78%
Income68.30M PEG1.96 EPS next Q1.37 Inst Own- Short Float10.15% Perf Quarter-13.65%
Sales274.70M P/S7.13 EPS this Y-100.60% Inst Trans-0.17% Short Ratio11.78 Perf Half Y-3.24%
Book/sh48.66 P/B2.42 EPS next Y-30.88% ROA5.30% Target Price211.71 Perf Year-24.56%
Cash/sh19.42 P/C6.06 EPS next 5Y15.00% ROE8.90% 52W Range102.01 - 219.75 Perf YTD-23.81%
Dividend- P/FCF- EPS past 5Y-15.10% ROI2.90% 52W High-45.13% Beta1.13
Dividend %- Quick Ratio11.00 Sales past 5Y21.00% Gross Margin77.50% 52W Low18.20% ATR8.07
Employees155 Current Ratio11.90 Sales Q/Q55.00% Oper. Margin25.60% RSI (14)34.78 Volatility5.67% 5.65%
OptionableYes Debt/Eq0.39 EPS Q/Q292.10% Profit Margin24.90% Rel Volume0.81 Prev Close117.69
ShortableYes LT Debt/Eq0.39 EarningsNov 09 AMC Payout0.00% Avg Volume136.99K Price120.57
Recom1.90 SMA20-12.78% SMA50-18.64% SMA200-10.23% Volume98,685 Change2.45%
Apr-14-21Resumed Stephens Overweight $200
Feb-04-21Reiterated H.C. Wainwright Buy $229 → $310
Oct-06-20Initiated Barclays Overweight $156
Mar-24-20Downgrade Argus Buy → Hold
Mar-10-20Initiated Guggenheim Neutral
Feb-06-20Initiated The Benchmark Company Buy $135
Sep-19-19Upgrade Barclays Equal Weight → Overweight $110 → $132
Jun-11-19Initiated Barclays Equal Weight $131
May-03-19Reiterated H.C. Wainwright Buy $254 → $214
Mar-06-19Reiterated H.C. Wainwright Buy $281 → $254
Oct-29-18Upgrade ROTH Capital Neutral → Buy
Oct-02-18Reiterated H.C. Wainwright Buy $270 → $280
Sep-11-18Reiterated Argus Buy $260 → $300
Aug-17-18Initiated Goldman Neutral $256
Aug-08-18Downgrade ROTH Capital Buy → Neutral
Jun-21-18Initiated Argus Buy $260
Dec-27-17Reiterated H.C. Wainwright Buy $163 → $169
Sep-05-17Resumed H.C. Wainwright Buy $150
Oct-05-16Reiterated H.C. Wainwright Buy $146 → $160
Aug-05-16Downgrade Deutsche Bank Hold → Sell $104 → $110
Jan-10-22 10:07AM  
Dec-28-21 12:38AM  
Dec-27-21 11:38PM  
10:38PM  
10:04AM  
Dec-26-21 08:39AM  
Dec-22-21 08:00AM  
Dec-21-21 04:01PM  
Dec-20-21 01:17AM  
Dec-13-21 10:00AM  
Dec-08-21 05:38PM  
Dec-07-21 04:38PM  
Nov-26-21 02:37PM  
Nov-15-21 11:38AM  
Nov-11-21 05:08PM  
10:11AM  
08:08AM  
Nov-10-21 12:23PM  
09:26AM  
12:32AM  
Nov-09-21 06:15PM  
04:02PM  
04:01PM  
Nov-03-21 05:51AM  
Oct-26-21 04:01PM  
Oct-22-21 03:00PM  
Oct-21-21 01:13PM  
09:00AM  
Sep-27-21 09:55AM  
Sep-22-21 05:10PM  
Sep-20-21 12:47PM  
Aug-30-21 07:00PM  
04:01PM  
Aug-16-21 02:53PM  
10:00AM  
Aug-05-21 09:11AM  
Jul-30-21 10:46AM  
02:02AM  
Jul-29-21 06:05PM  
04:01PM  
Jul-28-21 04:00PM  
05:47AM  
Jul-22-21 03:03PM  
Jul-21-21 09:00AM  
Jul-19-21 08:00AM  
Jul-16-21 09:00AM  
Jul-14-21 04:01PM  
Jun-28-21 10:13AM  
09:47AM  
Jun-02-21 11:30AM  
May-29-21 05:01AM  
May-10-21 01:10PM  
May-05-21 08:48AM  
May-04-21 11:04AM  
06:05AM  
12:00AM  
May-03-21 05:20PM  
04:01PM  
02:45PM  
Apr-26-21 12:31PM  
Apr-22-21 04:01PM  
06:40AM  
Mar-17-21 08:00AM  
Mar-15-21 01:05PM  
Mar-10-21 01:36PM  
11:17AM  
Mar-09-21 09:40AM  
Mar-05-21 11:30AM  
Feb-25-21 09:55AM  
Feb-17-21 12:44PM  
Feb-11-21 01:40PM  
Feb-10-21 01:40PM  
Feb-09-21 06:40AM  
Feb-06-21 02:38AM  
Feb-05-21 04:39PM  
Feb-04-21 01:54PM  
08:56AM  
03:15AM  
Feb-03-21 01:30PM  
07:58AM  
07:30AM  
06:30AM  
Feb-02-21 11:59AM  
Feb-01-21 02:57PM  
Jan-29-21 05:21PM  
Jan-28-21 08:04PM  
06:34PM  
Jan-27-21 01:06PM  
05:34AM  
Jan-20-21 12:45PM  
08:30AM  
Jan-19-21 04:18PM  
Jan-13-21 08:30AM  
Dec-23-20 10:15AM  
Dec-21-20 08:30AM  
Dec-18-20 02:43PM  
Dec-17-20 09:19AM  
Dec-06-20 03:59AM  
Nov-29-20 11:30AM  
Nov-23-20 08:30AM  
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LAMATTINA JOHN LDirectorNov 16Option Exercise32.304,835156,17030,233Nov 17 05:06 PM
LAMATTINA JOHN LDirectorNov 16Sale161.864,835782,57925,398Nov 17 05:06 PM
HIGGINS JOHN LChief Executive OfficerNov 12Sale160.503,000481,500335,095Nov 12 07:31 PM
FOEHR MATTHEW WPresident and COONov 11Option Exercise28.5412,188347,818177,685Nov 12 04:54 PM
FOEHR MATTHEW WPresident and COONov 11Sale163.0211,1601,819,255166,525Nov 12 04:54 PM
FOEHR MATTHEW WPresident and COOAug 04Option Exercise29.239,982291,745173,195Aug 05 04:44 PM
FOEHR MATTHEW WPresident and COOAug 04Sale109.678,840969,507164,355Aug 05 04:44 PM
FOEHR MATTHEW WPresident and COOMay 28Option Exercise56.261,75598,736164,355Jun 01 04:59 PM
KOZARICH JOHN WDirectorMay 11Option Exercise10.124,83548,93034,543May 13 08:57 PM
KOZARICH JOHN WDirectorFeb 22Option Exercise10.122,50025,30029,708Feb 23 05:18 PM
Davis Todd CDirectorFeb 11Option Exercise195.912,474484,68150,152Feb 12 06:23 PM
Davis Todd CDirectorFeb 10Sale213.145,0831,083,41047,678Feb 12 06:23 PM
Sabba Stephen LDirectorFeb 09Option Exercise11.3214,670166,13839,101Feb 11 04:06 PM
Sabba Stephen LDirectorFeb 09Sale208.5314,6703,059,12324,431Feb 11 04:06 PM
HIGGINS JOHN LChief Executive OfficerFeb 05Option Exercise12.16114,6661,394,017346,030Feb 09 06:08 PM
HIGGINS JOHN LChief Executive OfficerFeb 05Sale203.4054,66611,119,239286,030Feb 09 06:08 PM
FOEHR MATTHEW WPresident and COOFeb 04Option Exercise23.0745,5471,050,890212,745Feb 05 05:03 PM
FOEHR MATTHEW WPresident and COOFeb 04Sale176.8644,5477,878,582168,198Feb 05 05:03 PM
Berkman Charles SSVP, Gen. Counsel & SecretaryFeb 04Sale178.5018,0973,230,37628,906Feb 05 05:03 PM
HIGGINS JOHN LChief Executive OfficerJan 27Option Exercise17.6670,0001,236,400283,422Jan 27 07:04 PM
Davis Todd CDirectorJan 27Option Exercise113.502,456278,75652,761Jan 27 07:02 PM
HIGGINS JOHN LChief Executive OfficerJan 27Sale182.0040,0007,280,000243,422Jan 27 07:04 PM